Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

What Was Tested

This randomized controlled trial paper looks at Octreotide and Somatostatin.

The researchers enrolled 42 patients with severe PLD resulting from autosomal dominant PKD (ADPKD) or autosomal dominant PLD (ADPLD) in a randomized, double-blind, placebo-controlled trial of octreotide, a long-acting somatostatin analogue.

The primary end point was percent change in liver volume from baseline to 1 year, measured by MRI.

Who Took Part

According to the abstract, 42 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The patients were allocated by chance, so the Octreotide group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Octreotide.

A placebo (an inactive look-alike) gave the Octreotide group a baseline to be compared against.

The timeline in the abstract includes 1 year.

What Was Measured

The primary end point was percent change in liver volume from baseline to 1 year, measured by MRI.

Secondary end points were changes in total kidney volume, GFR, quality of life, safety, vital signs, and clinical laboratory tests.

The subject headings attached to it are Glomerular Filtration Rate, Kidney, Liver, Liver Diseases, Octreotide, Organ Size and Polycystic Kidney, Autosomal Dominant.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Octreotide and Somatostatin in 42 patients over 1 year.

The publication is from 2010 (Journal of the American Society of Nephrology : JASN), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.